ISBB Finals Flashcards

Pretransfusion, Blood Components, Adverse Reactions

1
Q
  • Is diagnosed when dyspnea occurs within 24 hours post transfusion
  • caused by increased intravascular volume due to excessive transfused fluid and/or too rapid of an infusion rate and the inability of the patient to accommodate the volume of transfused products due to impaired pulmonary, cardiac, or renal function.
A

Transfusion-Associated Dyspnea (TAD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  • a nonspecific sign that could be seen in a variety of other transfusion reactions or as part of the patient’s underlying condition
  • when hypotension is seen alone during or within 1 hour after the transfusion is finished.

Adult: BP systolic drop of** ≥30 mm Hg** and systolic BP ≤80 mm Hg
Children: 25% drop in the baseline systolic BP

A

Hypotensive Transfusion Reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  • Are one of the most common adverse TR
  • Fever is greater than 100.4 F (38C)
  • Or 1.8F (1.0C) from the pretransfusion level occurring during or **within 4 hours **after the end of the transfusion
  • or** chills and/or rigors** are present
A

**Febrile Nonhemolytic Transfusion Reaction (FNHTR)
**

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  • The most common reactions seen with platelet and plasma transfusion
    -* IgA deficiency* is defined as undetectable serum IgA (less than 0.5 mg/dL). Most IgA-related anaphylactic reactions occur in IgA-deficient persons with detectable class-specific anti-IgA antibodies.
  • However, reactions do not occur in the majority of patients, and anaphylaxis is rare.
A

Allergic Transfusion Reaction (ATRs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
  • Headache is the most commonly reported symptom
  • Fever, chills, nausea, vomiting, abdominal pain, diarrhea, facial flushing, urticaria, itching, muscular cramps, and back pain are other common symptoms
  • albumin, intravenous immune globulin (IVIG), and human-derived factor concentrates, can be associated with adverse events other than viral transmission.
A

Adverse Reactions to Infusion of Plasma-Derived Products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  • A clinical syndrome developing from 2 days to 6 weeks after transfusion characterized by the typical skin rash seen and other forms of GVHD, diarrhea, fever, enlarged liver, elevated liver enzymes, marrow aplasia, and/or pancytopenia.

- Definitive Diagnosis: skin biopsy (occasionally liver)

A

Transfusion-Associated Graft-vs- Host Disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  • is a rare transfusion reaction in which there is a severe and sudden drop in the platelet count, usually occurring 5 to 10 days after transfusion due to alloimmunization to platelet-specific antibodies from prior transfusion or pregnancy
  • Diagnosis: Thrombocytopenia
A

Post-Transfusion Purpura

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

**Adverse Metabolic Effects of Transfusion
**
- excessive amounts of citrate can enter the circulation in massive transfusion or in patients with severe liver disease.
- can cause hypocalcemia and hypomagnesemia. In addition, metabolic alkalosis can de velop from bicarbonate produced from citrate metabolism.

A

Citrate toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

**Adverse Metabolic Effects of Transfusion
**

  • During RBC storage, intracellular potassium slowly leaks from aging RBCs causing increased potassium in the super natant.
  • is very uncommon in massive trans fusion in adults, but it is of special concern in neonatal transfusions, especially in premature infants.
  • The signs and symptoms of increased potassium are due to neuromuscular and cardiac effects
A

Hyperkalemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  • causes:
    Viruses, bacteria, non-infectious agents such as chemicals (drugs and alcohol), ionizing radiation, and autoimmune processes
  • As complication:
    EBV, CMV, parvovirus, and HSV (these are not considered as hepatitis viruses)
A

Transfusion-Associated Hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  • It is a single-stranded RNA lipid-enveloped virion that is common in Africa, West Asia, and the Middle East.
  • The infection in humans has an incubation period of approximately 3 to 14 days following the mosquito bite, with symptoms lasting 3 to 6 days
A

West Nile Virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

WNV detection method

A

ELISA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
  • symptoms include fever, headache, rash, and muscle and joint pain.
  • It is estimated that less than 20% of infected individuals experience symptoms.
  • has been associated with severe neurological complications including increased rates of microcephaly and fetal brain anomalies during pregnancy and Guillain-Barre syndrome.
A

Zika Virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Primary disease symptoms include high fever, severe joint pain, headache, muscle pain, rash, and leukopenia

A

Chikungunya Virus (CHIKV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

is the most common risk of infection due to transfusion of blood

A

Bacterial contamination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

are the most common bacterial contaminants of blood

A

Staphylococcus epidermidis or S. aureus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

According to the CDC, –––– is the most common isolate found in RBC units, followed by the Pseudomonas species.

A

Yersinia enterolitica

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

strongly indicates contamination. COLOR.

A

dark purple or black

clots in the unit and hemolysis may also indicate contamination.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Red Cells Shelf Life

a. ACD-A, CPD, CP2D: 21 days
CPDA-1: 35 days
a. ACD-A, CPD, CP2D: 35 days
CPDA-1: 21 days

A

a. ACD-A, CPD, CP2D: 21 days
CPDA-1: 35 days

a. ACD-A, CPD, CP2D: 35 days
CPDA-1: 21 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Platelets shelf life

a. 24 hours
b. 1-6 days
c. 5 days

A

Platelets shelf life

a. 24 hours
b. 1-6 days
c. 5 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

The tubing that connects blood bags is usually made of

A

polyvinyl chloride (PVC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Mechanical devices that apply pressure to the blood bag, which allows blood components to flow from one bag to another by way of the integrated tubing system

A

Plasma Expressors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

RBCs + plasma

a. 5,000 x g, 5 minutes
b. 2,000 x g, 3 minutes
c. 5,000 x g, 7 minutes

A

RBCs + plasma

a. 5,000 x g, 5 minutes
b. 2,000 x g, 3 minutes
c. 5,000 x g, 7 minutes

24
Q

Collecting whole blood and transforming into components

A

centrifugation

25
Q

Collecting targeted components

A

Apheresis

26
Q

Plasma concentrated, sterile specific proteins, obtained
from large pools of donor t**hrough plasma fractionation. **

Ex: albumin, RHIG, HBIG, freeze dried factor VIII and IX.

A

** Plasma derivative**

27
Q

Rejuvenation solutions: PIPA

A

Phosphate, Inositol, Pyruvate, Adenine

28
Q

is the only FDA-approved rejuvenation solution sold in the US

A

Rejuvesol (enCyte Systems)

29
Q
  • invaluable for preserving selected autologous and rare units of blood for later use
  • The process by which ATP and 2,3 DPG levels are restored or enhanced by metabolic alterations.
A

Rejuvenation of RBCs

30
Q
  • an RBC membrane stabilizing reagent
  • protects against storage- related hemolysis
A

Mannitol

31
Q

Benefits of RBC Additive Solutions

A
  1. Extends the shelf-life of RBCs to 42 days by adding nutrients
  2. Allows for the harvesting of more plasma and platelets from the unit
  3. Produces a packed RBC of** lower viscosity **that is easier to infuse. Reduces hematocrit from 65% to 80% to around 55% to 65% (300 to 400 mL)
32
Q
  • added to the RBCs after removal of the plasma with or without platelets
  • Removal of the plasma component during the preparation of packed RBCs removed much of the nutrients needed to maintain RBCs during storage
A

Additive Solutions

33
Q

Additive solution volume

A

Volume: 100 mL to RBC conc from 450 mL blood collection

must be added within 72 hours

34
Q

Random Donor Platelet (RDP)
storage temperature

a. 1-6 C
b. 37 C
c. 20-24 C

A

Random Donor Platelet (RDP)
storage temperature

a. 1-6 C
b. 37 C
c. 20-24 C

35
Q

Random Donor Platelet (RDP)
must be processed within

a. 6-8 hrs
b. 24 hrs
c. 4 hours

with constant agitation

A

Random Donor Platelet (RDP)
must be processed within

a. 6-8 hrs
b. 24 hrs
c. 4 hours

36
Q

Platelets obtained from an apheresis donation
- Higher yield, contain 4 to 6 times as many platelets as RDP
- Minimal RBC contamination

A

Single Donor Platelet (SDP)

37
Q

Indications:
- Patients who are unresponsive to RDPs due to HLA alloimmunization
- Or to limit the platelet exposure from multiple donors (must be divided into aliquots if small-volume transfusion are required)

a. SDP
b. RDP
c. Platelets, irradiated
d. Platelets, leukoreduced

A

Indications:
- Patients who are unresponsive to RDPs due to HLA alloimmunization
- Or to limit the platelet exposure from multiple donors (must be divided into aliquots if small-volume transfusion are required)

**a. SDP
**b. RDP
c. Platelets, irradiated
d. Platelets, leukoreduced

38
Q

One unit of plasma contains:

A

Approx. 300 mg fibrinogen per 100 mL
And 1 unit of activity per mL of each of the stable clotting factors

39
Q

Indications:
1. Multiple coagulation factor deficiencies (Liver disease, DIC)
2. For isolated factor deficiencies when no component is available 3. Antithrombin III deficiency
4. Patients on anticoagulants who are bleeding or require surgery; reversal of warfarin/coumadin overdose

a. plasma
b. SDP
c. RDP
d. RBC

A

Indications:
1. Multiple coagulation factor deficiencies (Liver disease, DIC)
2. For isolated factor deficiencies when no component is available 3. Antithrombin III deficiency
4. Patients on anticoagulants who are bleeding or require surgery; reversal of warfarin/coumadin overdose

**a. plasma **
b. SDP
c. RDP
d. RBC

40
Q
  • Is the cold-precipitated concentration of FVIII (AKA-antihemophilc factor)
  • The process of isolating FVIII also harvests fibrinogen, FXIII, von Willebrand factor, cryoglobulin, and fibronectin
A

Cryoprecipitated AHF

41
Q

INDICATIONS

Treatment of FXIII deficiency, as a source of fibrinogen for hypofibrinogenemia, and as a secondary line of treatment for classic hemophilia (hemophilia A) and vWD.

Has also been used to make fibrin glue, a substance composed of cryoprecipitate (fibrinogen) and topical thrombin.

A

Cryoprecipitated Antihemophilic Factor

42
Q
  • Is the plasma from which the cryoprecipitate concentrate has been harvested.
  • Contains the residual albumin; factors II, V, VII, IX, X, XI; and ADAMTS13
    -Cannot be used as substitute for FFP, PF24, or thawed plasma.

a. Cryoprecipitated Antihemophilic Factor
b. Cryo-Poor Plasma (CPP)
c. AKA: Granulocyte pheresis
d. Platelets

A
  • Is the plasma from which the cryoprecipitate concentrate has been harvested.
  • Contains the residual albumin; factors II, V, VII, IX, X, XI; and ADAMTS13
    -Cannot be used as substitute for FFP, PF24, or thawed plasma.

a. Cryoprecipitated Antihemophilic Factor
b. Cryo-Poor Plasma (CPP)
c. AKA: Granulocyte pheresis
d. Platelets

43
Q

he process of removing the extracellular solution and replacing with normal saline

A

washing

44
Q

Indications:

Neonates whose platelet counts fall below 50,000/mL and who are experiencing bleeding.

A

Platelet Aliquots

45
Q
A
46
Q
A
47
Q
  • Allow for multiple blood components to be transfused at a single event
  • The components pooled may be all the same or a combination of components depending on the patient’s need.
A

pooling

48
Q

Frozen, Deglycerolized RBC
shelf life

a. 24 hours
b. 1 year
c. 5 days
d. 10 years

A

Frozen, Deglycerolized RBC
shelf life

a. 24 hours
b. 1 year
c. 5 days
d. 10 years

49
Q

Made of large molecules that form a shell around the cell, preventing loss of water and subsequent dehydration
* Ex: Hydroxyethyl starch (HES) and dimethylsulfoxide

a. penetrating
b. nonpenetrating

A

Made of large molecules that form a shell around the cell, preventing loss of water and subsequent dehydration
* Ex: Hydroxyethyl starch (HES) and dimethylsulfoxide

a. penetrating
b. nonpenetrating

50
Q
  • Involves small molecules that cross the cell membrane into the cytoplasm
  • The osmotic force of the agent prevents water from migrating outward as
    extracellular ice is formed, preventing intracellular dehydration * Ex: Glycerol

a. penetrating
b. nonpenetrating

A
  • Involves small molecules that cross the cell membrane into the cytoplasm
  • The osmotic force of the agent prevents water from migrating outward as
    extracellular ice is formed, preventing intracellular dehydration * Ex: Glycerol

a. penetrating
b. nonpenetrating

51
Q

Indications:

  • Patients with **hemophilia A or B **who have circulating antibodies or inhibitors
  • In patients with** congenital factor VII deficiency**
  • Patients with Glanzmann thrombasthenia

a. Activated FVII (Factor VIIa)
b. Factor VIII Concentrates (FVIII)
c. Factor IX Concentrates

A

Indications:

  • Patients with **hemophilia A or B **who have circulating antibodies or inhibitors
  • In patients with** congenital factor VII deficiency**
  • Patients with Glanzmann thrombasthenia

    a. Activated FVII (Factor VIIa)
    b. Factor VIII Concentrates (FVIII)
    c. Factor IX Concentrates
52
Q

contains significant levels of vit. K-dependent factors II, VII, IX, and X)

a. Prothrombin complex concentrates
b. Factor IX
c. rFIX

A

contains significant levels of vit. K-dependent factors II, VII, IX, and X)

a. Prothrombin complex concentrates
b. Factor IX
c. rFIX

53
Q

Prepared from:
Pooled plasma by cold ethanol fractionation

Indications:
* Patients with** immunodeficiency diseases** (i.e. severe combined immunodeficiency and Wiskott-Aldrich syndrome)
* Provides passive antibody prophylaxis against hepatitis and herpes

a. Normal Serum Albumin
b. Immune Serum Globulin
c. PPF or Plasma Protein Fraction

A

Prepared from:
Pooled plasma by cold ethanol fractionation

Indications:
* Patients with** immunodeficiency diseases** (i.e. severe combined immunodeficiency and Wiskott-Aldrich syndrome)
* Provides passive antibody prophylaxis against hepatitis and herpes

a. Normal Serum Albumin
b. Immune Serum Globulin
c. PPF or Plasma Protein Fraction

54
Q

Indications:
- Patients who are hypovolemic and hypoproteinemic - In clinical settings for shock and burn patients

A

Plasma Protein Fraction

55
Q

*Indication:
Treatment of** ITP** and immunization against the D antigen

a. Rho (D) Immune Globulin
b. Immune Serum Globulin
c. Normal Serum albumin

A

*Indication:
Treatment of** ITP** and immunization against the D antigen

a. Rho (D) Immune Globulin
b. Immune Serum Globulin
c. Normal Serum albumin